GATA2 mutations cause a disease characterized by mycobacterial infection, monocytopenia, B- and NK-cell deficiency, with a high risk of progression to myelodysplasia (MDS) and acute leukemia. We report a patient affected by recurrent episodes of aphthous stomatitis since infancy and hematological features of GATA2 deficiency syndrome. He also had difficulties clearing Parvovirus B19 infection. GATA2 molecular analysis showed a mutation in exon 3. We followed him closely, monitoring his bone marrow every 6 months. After 1 year he developed refractory cytopenia (MDS), and therefore underwent HSCT from the HLA-matched (GATA2 wildtype) brother. He received treosulfan, fludarabine and thiotepa as conditioning and methotrexate and cyclosporine as GvHD prophylaxis post-transplantation. He is now 90 days post transplant and clinically well. He engrafted on day 23 and developed low grade GvHD successfully treated with steroids. High levels of donor engraftment were achieved in those hematopoietic compartments deficient pretransplantation. Here we illustrate the necessity to closely follow GATA2 deficiency patients and refer for HSCT in a timely manner.

Timely follow-up of a GATA2 deficiency patient allows successful treatment / Ciullini Mannurita, Sara; Vignoli, Marina; Colarusso, Gloria; Tucci, Fabio; Veltroni, Marinella; Frenos, Stefano; Tintori, Veronica; Aricò, Maurizio; Bigley, Venetia; Collin, Matthew; Favre, Claudio; Gambineri, Eleonora. - In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. - ISSN 0091-6749. - ELETTRONICO. - 138:(2016), pp. 1480-1483.e4-1483.e4. [10.1016/j.jaci.2016.06.004]

Timely follow-up of a GATA2 deficiency patient allows successful treatment

CIULLINI MANNURITA, SARA;VIGNOLI, MARINA;GAMBINERI, ELEONORA
2016

Abstract

GATA2 mutations cause a disease characterized by mycobacterial infection, monocytopenia, B- and NK-cell deficiency, with a high risk of progression to myelodysplasia (MDS) and acute leukemia. We report a patient affected by recurrent episodes of aphthous stomatitis since infancy and hematological features of GATA2 deficiency syndrome. He also had difficulties clearing Parvovirus B19 infection. GATA2 molecular analysis showed a mutation in exon 3. We followed him closely, monitoring his bone marrow every 6 months. After 1 year he developed refractory cytopenia (MDS), and therefore underwent HSCT from the HLA-matched (GATA2 wildtype) brother. He received treosulfan, fludarabine and thiotepa as conditioning and methotrexate and cyclosporine as GvHD prophylaxis post-transplantation. He is now 90 days post transplant and clinically well. He engrafted on day 23 and developed low grade GvHD successfully treated with steroids. High levels of donor engraftment were achieved in those hematopoietic compartments deficient pretransplantation. Here we illustrate the necessity to closely follow GATA2 deficiency patients and refer for HSCT in a timely manner.
2016
138
1480-1483.e4
1483.e4
Ciullini Mannurita, Sara; Vignoli, Marina; Colarusso, Gloria; Tucci, Fabio; Veltroni, Marinella; Frenos, Stefano; Tintori, Veronica; Aricò, Maurizio; ...espandi
File in questo prodotto:
File Dimensione Formato  
Ciullini_GATA2_JACI 2016.pdf

Accesso chiuso

Descrizione: Articolo principale
Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 1.23 MB
Formato Adobe PDF
1.23 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1061425
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact